Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chatbot may calm nerves after a prostate cancer diagnosis

NCT ID NCT07804030

Symptom relief Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether an AI-powered support tool, accessed through a WeChat Mini Program, can reduce anxiety in men recently diagnosed with metastatic prostate cancer. Participants are randomly assigned to use the platform with the AI agent or without it for the first two weeks. The AI agent answers questions about the disease and its management using clinician-reviewed materials. Researchers measure changes in anxiety, illness perception, sleep quality, and patient satisfaction over four weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI agent-assisted patient-centered support delivered through a WeChat Mini Program
What this could lead to
If it works, this AI-based support could become a scalable way to reduce anxiety and improve quality of life for people facing a new cancer diagnosis.
What could go wrong
The trial is small and early, and the AI agent's responses may not always be accurate or helpful. Benefits are measured over just a few weeks, so any effect may be short-lived.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Newly diagnosed prostate adenocarcinoma confirmed by histopathology or cytopathology; 2. Metastatic disease confirmed by imaging or pathology; 3. Diagnosis of metastatic prostate cancer within 2 weeks before enrollment; 4. Aged 18-80 years; 5. A GAD-7 score of 5 or higher at screening; 6. Adequate cognitive ability to understand and participate in the study; 7. Adequate language comprehension and ability to complete the study questionnaires independently; 8. Access to a smartphone and an internet connection required to use the study platform; 9. Provision of written informed consent. Exclusion Criteria: 1. An acute or unstable psychiatric disorder, such as severe depressive or anxiety disorder, or severe insomnia requiring urgent specialist care; 2. History of or current cognitive impairment, such as intellectual disability or Alzheimer's disease; 3. A requirement for emergency surgery within 72 hours after enrollment; 4. Planned prostate cancer-directed radiotherapy, surgery, or chemotherapy during the study period; 5. Current participation in another interventional clinical trial; 6. A request from the participant's family to withhold the diagnosis or disease-related information from the participant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder metastatic prostate carcinoma Patient Satisfaction prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350011, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.